Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief Science Officer | March 07, 2025 | March 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date March 07, 2025 · Filed March 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,552 |
Ending reported balance
After 2025-03-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-03-07 · Grant · Acquired 115,000 · Balance 376,414 F1: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Row 2 · 2025-03-07 · Tax withholding · Disposed 12,859 · Balance 363,555 F2: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Row 3 · 2025-03-09 · Tax withholding · Disposed 15,431 · Balance 348,124 F2: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Row 4 · 2025-03-10 · Tax withholding · Disposed 4,572 · Balance 343,552 F2: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2035-03-07 | Direct | 65,000 |
Reported balance
After 2025-03-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-07 · Grant · Acquired 65,000 · Balance 65,000 F3: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.
F3: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2025 Filed Mar 11, 2025 21:49 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 4,572 | $2.54 | $11,612.88 |
DisclosureSEC source: 0001214659-25-004228 · marketforms-68577.xml · nonDerivative · entry 4 Wargacki Stephen · CIK 0001960165 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,552 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 09, 2025 Filed Mar 11, 2025 21:49 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 15,431 | $2.65 | $40,892.15 |
DisclosureSEC source: 0001214659-25-004228 · marketforms-68577.xml · nonDerivative · entry 3 Wargacki Stephen · CIK 0001960165 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,124 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:49 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001214659-25-004228 · marketforms-68577.xml · derivative · entry 5 Wargacki Stephen · CIK 0001960165 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-03-07 F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:49 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 12,859 | $2.65 | $34,076.35 |
DisclosureSEC source: 0001214659-25-004228 · marketforms-68577.xml · nonDerivative · entry 2 Wargacki Stephen · CIK 0001960165 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,555 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:49 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-004228 · marketforms-68577.xml · nonDerivative · entry 1 Wargacki Stephen · CIK 0001960165 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,414 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| May 10, 2024 Filed May 13, 2024 17:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-008874 · marketforms-65653.xml · nonDerivative · entry 1 Wargacki Stephen · CIK 0001960165 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,963 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 17:46 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 1,687 | $4.88 | $8,232.56 |
DisclosureSEC source: 0001214659-24-004391 · marketforms-65149.xml · nonDerivative · entry 2 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,963 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 17:46 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 11,269 | $4.88 | $54,992.72 |
DisclosureSEC source: 0001214659-24-004391 · marketforms-65149.xml · nonDerivative · entry 1 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,650 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 09, 2024 Filed Oct 2, 2024 18:15 UTC Amendment | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 19,505 | $4.88 | $95,184.40 |
DisclosureSEC source: 0001214659-24-017010 · marketforms-67100.xml · nonDerivative · entry 1 Wargacki Stephen · CIK 0001960165 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,414 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 . Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:34 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 56,250 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001214659-24-004302 · marketforms-64695.xml · derivative · entry 3 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2034-03-07 F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:34 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-004302 · marketforms-64695.xml · nonDerivative · entry 2 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,919 F3 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 67,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-010924 · marketforms-61880.xml · derivative · entry 1 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| May 05, 2023 Filed May 5, 2023 20:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 67,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-006560 · marketforms-61242.xml · derivative · entry 1 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| March 10, 2023 Filed Mar 11, 2024 14:34 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 1,981 | $0.79 | $1,572.32 |
DisclosureSEC source: 0001214659-24-004302 · marketforms-64695.xml · nonDerivative · entry 1 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,419 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. F2 · balance_after: The original Form 3, filed on 1/1/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares vested that occurred on 3/10/22 as a total of 4,663 shares vested and owned when in fact 3,107 shares of the Issuer's common stock were owned, net of taxes withheld. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 1,556 shares reflecting share withheld for the payment of taxes. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 20:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-003689 · marketforms-59532.xml · nonDerivative · entry 1 Wargacki Stephen · CIK 0001960165 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,956 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.